The Sciety syndicate invests in Predicare - the company making emergency care more effective
The Sciety investor syndicate has now completed an investment of MSEK 9 in Predicare that has developed RETTS, a system used by the majority of Sweden’s emergency units. The new capital will be used for expansion into selected European markets and a further development of the company’s product portfolio.
The Gothenburg based company, Predicare, was founded by an emergency unit doctor and nurse at Sahlgrenska University Hospital who identified the need of a more structured means of assessing care requirements in patients visiting emergency and accident wards. Today, their system RETTS is digitalised and is a part of the daily operations of emergency units and ambulances in Sweden.
The system is also used by a major portion of Norway’s emergency units and the company is now targeting a broader expansion in Europe. The newly completed financing is a stage in strengthening the company for this expansion and in further developing its product portfolio.
“We are very satisfied with the cooperation with Sciety. They have managed the process in a very good manner and have provided Predicare with access to capital for our continued growth,” states Mathias Myrén, CEO of Predicare.
The company has already received queries from potential clients in Europe and Asia.
“We have had discussions with a major healthcare provider in China who has shown interest in the RETTS system. Recently we were also contacted by a healthcare company operating hospitals and ambulances services in Austria. At the same time, Predicare has discussions with strategically important hospitals in Europe,” notes Mathias Myrén.
Predicare differs from many other innovative technological companies – it has grown and achieved profitability in Sweden without the need of external capital. It is first, now, when Predicare focuses on international operations that they have chosen to raise capital to speed up expansion.
“Sciety has followed Predicare’s progress during a number of years and chose to invest as the company has a clinically proven product, scalable business model and operates in a growing global market,” states Andreas Lindblom, CEO of Sciety.
Andreas Lindblom, CEO of Sciety: email@example.com, +46 (0) 70 375 73 73.
Sciety is the leading investor syndicate in the Nordics with an exclusive focus on life science and health tech. We combine experience from life science and finance to select promising companies in the industry. Sciety invests own funds in all companies that pass our selection process and offer the network to co-invest on the same terms. The network comprises venture capital firms, family offices and business angels. Sciety’s vision is that innovations in life science reach their full potential.